论文部分内容阅读
目的:探讨依达拉奉治疗急性脑梗死患者的临床疗效,以及减轻脑水肿和降低血清超敏C-反应蛋白水平的价值。方法:选取符合标准的急性脑梗死患者100例,随机分为观察组和对照组各50例,2组患者均给予常规治疗,同时,观察组加用依达拉奉注射液30 mg,静脉滴注,bid;对照组给予吡拉西坦注射液8.0g,静脉滴注,qd;2组患者疗程均为14 d。分别于治疗前和治疗后7,14 d评价患者的脑水肿体积和血清超敏C-反应蛋白水平;疗程结束后,评价临床治疗效果。结果:观察组总有效率为86.00%,明显高于对照组的70.00%,二者差异有显著性(P<0.05);血清超敏C-反应蛋白水平及脑水肿体积较治疗前均下降(P<0.05),但观察组下降更明显(P<0.01)。结论:依达拉奉可以显著减轻急性脑梗死患者的脑水肿程度,改善神经缺损症状,提高临床疗效,值得临床推广应用。
Objective: To investigate the clinical efficacy of edaravone in the treatment of patients with acute cerebral infarction, as well as the value of reducing cerebral edema and decreasing the level of serum C-reactive protein. Methods: A total of 100 acute cerebral infarction patients were selected and randomly divided into observation group (50 cases) and control group (50 cases). The patients in both groups were given routine treatment. Meanwhile, the observation group was treated with edaravone 30 mg intravenously Note, bid; control group was given piracetam injection 8.0g, intravenous infusion, qd; 2 patients were treated for 14 days. The volume of brain edema and the level of serum high-sensitivity C-reactive protein in patients before and after treatment were evaluated at 7 and 14 days after treatment. After the treatment, the clinical effect was evaluated. Results: The total effective rate in the observation group was 86.00%, which was significantly higher than that in the control group (70.00%) (P <0.05). The serum levels of C-reactive protein and brain edema decreased significantly P <0.05), but the observation group decreased more significantly (P <0.01). Conclusion: Edaravone can significantly reduce the degree of cerebral edema in patients with acute cerebral infarction, improve the symptoms of nerve defects and improve clinical efficacy, which is worthy of clinical application.